Loading...
•
Dec 31, 2020
PDS Biotechnology Q4 2020 Earnings Report
PDS Biotech reported financial results and provided a business update.
Key Takeaways
PDS Biotech reported a net loss of $14.8 million for the year ended December 31, 2020, compared to a net loss of $7.0 million for the previous year. Research and development expenses increased, while general and administrative expenses decreased. The company's cash balance as of December 31, 2020 was $28.8 million.
Achieved preliminary efficacy benchmark in the Phase 2 combination trial of PDS0101 led by the National Cancer Institute.
Initiated VERSATILE-002, a Phase 2 trial of lead investigational drug candidate PDS0101, in combination with standard of care KEYTRUDA® for first-line treatment of patients with metastatic or recurrent HPV-positive head and neck cancer.
Expanded consortium for development of PDS0203, a novel, Versamune®-based second-generation COVID-19 vaccine.
Received award commitment of up to $60 million from Brazil’s Ministry of Science, Technology and Innovation (MCTI) to fund clinical development and commercialization of PDS0203.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...